TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00882414
Drug: FERINJECT® (Ferric carboxymaltose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.
Study: NCT00882414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.
Study: NCT00943683
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral granules mixed with applesauce once daily at bedtime for 6 weeks
Study: NCT03773952
Drug: PBF-677
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral small molecule, antagonist of Adenosine A3 receptor (AA3R)
Study: NCT03773952
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT04672083
Drug: CPT31
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CPT31 (cholesterol-PIE12-2-trimer) is a novel D-peptide HIV entry inhibitor that binds with high affinity to a conserved hydrophobic pocket within the gp41 trimer
Study: NCT04672083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT00511303
Drug: STI571
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00215852
Drug: Alferon LDO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 IU, taken orally each evening, for 10 consecutive days while holding in the mouth for at least 2 minutes prior to swallowing, for 10 daysday 5 of each 28 day cycle.
Study: NCT00363714
Drug: AGN211745
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100microgram single intravitreal injection
Study: NCT00363714
Drug: AGN211745
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200microgram single intravitreal injection
Study: NCT00363714
Drug: AGN211745
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400microgram single intravitreal injection
Study: NCT00363714
Drug: AGN211745
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800microgram single intravitreal injection
Study: NCT00363714
Drug: AGN211745
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200microgram single intravitreal injection
Study: NCT02323022
Drug: IAC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment for initially diagnosed AML with IAC regimen, including Cladribine 5mg/msq/d (d1-5), Ara-C 100mg/msq/d(d1-7) and IDA 8mg/msq/d (d1-3)
Study: NCT02323022
Drug: IA regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 12mg/msq/d (d1-3)
Study: NCT00363714
Drug: AGN211745
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600microgram single intravitreal injection
Study: NCT00871481
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03404648
Drug: C-11 choline PET tracer
Normalized name: choline C-11
DrugBank: Choline C-11 (DB09563)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C-11 choline PET tracer, One dose, totally 12-14 millicurie (mCi), intravenous administration while patient is lying on the table.
Study: NCT00123929
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 every 3 weeks times 4
Study: NCT02792257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose
Study: NCT00622193
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet
Study: NCT02117349
Drug: Rescue treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin-containing hemostats included in standard care at the site
Study: NCT04246554
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ketorolac for pain control following ACL reconstruction surgery
Study: NCT04246554
Drug: Oxycodone-Acetaminophen
Normalized name: acetaminophen / oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone-acetaminophen for post-operative pain control
Study: NCT02768376
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction by propofl 1.5-2 mg/kg, Fentanyl 1-2 mic/kg and atracrium 0.5 mg/kg Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
Study: NCT02162888
Drug: Test Product (Bendamustine)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00820326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
Study: NCT03010540
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Effect Of Fentanyl Only On Emergence Delirium
Study: NCT02929524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
Study: NCT00135109
Drug: SPM 927
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05021718
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg) and Baclofen (10 mg) tablet twice a day for three weeks
Study: NCT00496366
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose of capecitabine is 1000 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2000 mg/m2).
Study: NCT01740336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to GDC-0941
Study: NCT01886196
Drug: Non-steroidal anti-inflammatory drug (Ibuprofen)
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg of ibuprofen administered after exercise training session 3 days per week
Study: NCT02109081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01915758
Drug: clindamycin1%/tretinoin 0.025% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: clindamycin1%/tretinoin 0.025% gel
Study: NCT01915758
Drug: vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle gel
Study: NCT00432237
Drug: MK0974 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00432237
Drug: MK0974 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00432237
Drug: MK0974 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00432237
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.
Study: NCT00627666
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00627666
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02582515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04337437
Drug: Genakumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/1ml/bottle, single subcutaneous injection.
Study: NCT04337437
Drug: Placebo for this trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.
Study: NCT02514044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03420534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
Study: NCT00331305
Drug: Placebo Pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01319006
Drug: GSK1278863A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg (x90=13um), oral tablet, single-dose with 7 day wash-out
Study: NCT01964248
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied 2 hours before blood sample
Study: NCT01964248
Drug: lidocaïne/prilocaïne 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application cream lidocaïne/prilocaïne (5%) 2 hours before blood sample
Study: NCT00283387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received oral lactose placebo, in two doses daily, for 2 months.
Study: NCT02236169
Drug: Atrovent CFC inhalation aerosol
Normalized name: Atrovent Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01319006
Drug: GSK1278863A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg (x90=29um), oral tablet, single-dose with 7 day wash-out
Study: NCT00357773
Drug: Azithromycin (T1225)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03415165
Drug: green tea buccal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: buccal tablet for 8 hrs 3 times aday
Study: NCT03415165
Drug: Corticosteroids Topical
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: kenacort in orabase 4 times aday
Study: NCT01319006
Drug: GSK1278863A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg (x90=41um), oral tablet, single-dose with 7 day wash-out
Study: NCT02595242
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 mg/m2 will be infused intravenously once 1-2 minutes in 20-30 ml saline on the first day during a treatment phase of 3 weeks.
Study: NCT03406533
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
Study: NCT03406533
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
Study: NCT01238120
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg BID and 8 hours apart
Study: NCT01238120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg BID and 8 hours apart
Study: NCT01892488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Control intervention:~Placebo for 5 days as supplement to standard of care for patients with AE-COPD
Study: NCT03759158
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet twice daily.
Study: NCT03522129
Drug: CT1812
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Study Drug
Study: NCT03522129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active study drug
Study: NCT02536586
Drug: LY3023414
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3023414 administered orally.
Study: NCT02635204
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily topical application for 14 days.
Study: NCT04552470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 matching placebo tablets taken twice a day (BID)
Study: NCT03475225
Drug: Placebo Oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: manufactured to mimic Cholecalciferol
Study: NCT00058461
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT03285620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose of matching placebo (oral solution) under fed or fasted conditions in part 1 and part 2.
Study: NCT00030784
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02114892
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcined magnesia capsules, 500 mg, three times per day before meals with a total dose per day of 1500 mg
Study: NCT02769091
Drug: TEV-45478
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg (2x40mg) tablets once daily for up to 24 weeks
Study: NCT02769091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01047683
Drug: AMR101 (ethyl icosapentate) - 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12)
Study: NCT01047683
Drug: AMR101 (ethyl icosapentate) - 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks (Weeks 1-12)
Study: NCT01047683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 4 capsules/day for 12 weeks (Weeks 1-12)
Study: NCT03885921
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet
Study: NCT03904680
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 2.5 mg tablet
Study: NCT03989830
Drug: second-line chemotherapy
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: choose appropriate regimen according to efficacy and adverse effects of first-line chemotherapy. q3W regimen, 6 cycles.
Study: NCT04870359
Drug: Prednisolone and/or AZA/MMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone and/or AZA/MMF
Study: NCT00839631
Drug: EC D-3263 HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC D-3263 HCl, capsules, 50 mg. Oral administration. Dose escalation cohorts (cycle one: single dose on Day 1, daily doses on day 8-28; subsequent cycles: 1 week drug holiday followed by 3 weeks of daily dosing). Expansion Cohort: daily dosing for 28 days followed by a single 7 day drug holiday (Cycle 1), continuing thereafter with daily dosing.
Study: NCT00190775
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered QD, orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
Study: NCT03547141
Drug: MBA-P01
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of MBA-P01 into the muscle of each contralateral foot in equal doses
Study: NCT01668277
Drug: 7.2% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01668277
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02248922
Drug: TIS or TIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)
Study: NCT02379858
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sugar pill-will be the same size and color as the Alvimopan capsule), 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
Study: NCT04536194
Drug: norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: to treat hypotension under general anesthesia with norepinephrine
Study: NCT04536194
Drug: dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: to treat hypotension under general anesthesia with dopamine
Study: NCT02956811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT03117335
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug 1:~Placebo(Sodium Chloride Injection),7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)
Study: NCT03117335
Drug: Sulijia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug 1:~Sulijia(Recombinant Endostatin Injection) Sulijia, 7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)
Study: NCT03338387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Other Names: Placebo (for Olbetam)
Study: NCT03097380
Drug: AZD2115
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2115
Study: NCT01339442
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02048904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 pill/day for 3 months
Study: NCT00441688
Drug: GI265235
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03369795
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 10mg once a week will be given for the first two weeks of the trial, followed by an increase in dose to 15mg or equivalent placebo once a week until week 16.
Study: NCT04132050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT03394950
Drug: rtPA
Normalized name: Sportpac Coldpac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysi with 0.9mg/kg rtPA, followed by other treatments according to guidelines
Study: NCT01446211
Drug: cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Severe subgroup: will receive intravenous cyclophosphamide pulses for at least 13 weeks and 22 weeks at maximum, followed by methotrexate + glucocorticoids after achieving a response with BVAS ≤ 2. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids .~Non-severe subgroup: will receive methotrexate + glucocorticoids (or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function).
Study: NCT00279747
Drug: meloxicam 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00279747
Drug: naproxen 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01929070
Drug: HCP1007
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01929070
Drug: Omarco and Crestor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03234114
Drug: Dual antithrombotc therapy-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus clopidogrel 75 mg q.d. (Sanofi, France)
Study: NCT03234114
Drug: Dual antithrombotc therapy-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus ticagrelor 90 mg b.i.d. (AstraZeneca, Britain)
Study: NCT04769557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00794586
Drug: FTI, AZLI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of 2 dosage combinations of fosfomycin and tobramycin inhaled twice daily for 28 days following 28 days of inhaled AZLI (Aztreonam Lysine for Inhalation)
Study: NCT00794586
Drug: Placebo, AZLI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume-matched placebo inhaled twice daily for 28 days following 28 days of AZLI (Aztreonam Lysine for Inhalation).
Study: NCT00083538
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02876978
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m\^2/day x 2 days
Study: NCT01587989
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15-25 mg orally weekly, Weeks 1-12
Study: NCT01587989
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15-25 mg orally weekly, Weeks 13-24
Study: NCT01587989
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: methotrexate placebo orally weekly, Weeks 13-24
Study: NCT04140214
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized hypertonic saline solution (6%)
Study: NCT04140214
Drug: Carbocysteine 750 MG
Normalized name: carbocysteine 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbocisteine tablet
Study: NCT00642330
Drug: oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
Study: NCT00642330
Drug: intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
Study: NCT02205450
Drug: Recombinant Somatropin
Approvals — FDA: no, EMA: no, PMDA: no